I spoke with Patty Fintak today, and those interested in this study should contact her to determine if they might qualify. Enrollment
should start early next year.
Patty Fintak, Research Coordinator with the Tumor Vaccine Group, UW/Seattle
(206) 543-6620 or e-mail
paf3@u.washington.edu
The trial isn't posted on UW's web site yet.
Here's a link from a news bulletin about the group sponsoring the trial, along with a link:
SOUTHWEST ONCOLOGY GROUP TO START PHASE II TRIAL OF OXFORD BIOMEDICA'S TROVAX IN BREAST CANCER
- Regulatory clearance for start of patient recruitment in 120-patient Phase II trial of TroVax in patients with late-stage breast cancer -
http://www.oxfordbiomedica.co.uk/news/2006-ob-18.htm
"Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces that the Southwest Oncology Group (SWOG), a US clinical trials cooperative group, has received regulatory clearance to commence a Phase II trial of Oxford BioMedica’s cancer immunotherapy, TroVax, in patients with late-stage breast cancer..."
Hybrid Mode
